Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bladder Clear all
Recruiting Phase 3 Interventional

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284
View directory record Official record
Conditions
High-risk Muscle Invasive Urothelial Carcinoma
Interventions
Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
19
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Active, not recruiting Not applicable Interventional

Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors

NCT00567684
View directory record Official record
Conditions
Bladder Cancer
Interventions
Computed Tomography Urography (CTU), Intravenous Urography (IVU)
Device · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Results available

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

NCT00022633
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
92
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 30, 2026, 4:06 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

NCT00773552
View directory record Official record
Conditions
Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions
solifenacin succinate, placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
20 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 30, 2026, 4:06 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma

NCT07874347
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Carcinoma
Interventions
BCG Solution, Best Practice, Cystoscopy, Home Health Encounter, Survey Administration
Biological · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantitative Studies of Urinary Bladder Sensation

NCT00903435
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Quantitative Sensory Testing and Stimulus
Other
Lead sponsor
Timothy Ness, MD
Other
Eligibility
19 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 30, 2026, 4:06 PM EDT
Completed No phase listed Observational Results available

Laser Therapy for Treatment of Urogenital Symptoms in Women

NCT03681678
View directory record Official record
Conditions
Genitourinary System; Disorder, Female, Burning Vagina, Dyspareunia, Irritation; Vagina, Menopause Related Conditions, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Tract Infections, Stress Urinary Incontinence
Interventions
fCO2 Laser Therapy Group
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

NCT00306150
View directory record Official record
Conditions
Blood Loss, Surgical, Postoperative Hemorrhage
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

NCT02015104
View directory record Official record
Conditions
Bladder Cancer
Interventions
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 30, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects

NCT01029015
View directory record Official record
Conditions
Bladder Function
Interventions
cystometry, polysomnography
Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 30, 2026, 4:06 PM EDT
Not listed Phase 3 Interventional

Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms

NCT00094874
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Acupuncture
Procedure
Lead sponsor
The Mary Elizabeth Groff Surgical Medical Research and Education Charitable Trust
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 4:06 PM EDT
Terminated Phase 3 Interventional

Refractory Urge Incontinence and Botox Injections

NCT00373789
View directory record Official record
Conditions
Urinary Incontinence, Detrusor Overactivity, Urinary Urgency, Urge Urinary Incontinence
Interventions
Botulinum Toxin A, bladder detrusor muscle injection, Vehicle saline as placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

NCT03844412
View directory record Official record
Conditions
Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome, Irritable Bowel Syndrome, Migraines, Tension Headache, Endometriosis, Interstitial Cystitis, Back Pain, Chronic Fatigue Syndrome
Interventions
5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream, Placebo pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Recruiting Phase 1 Interventional

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)
Interventions
MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab, vobramitamab tavatecan
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Recruiting Phase 4 Interventional

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

NCT04305743
View directory record Official record
Conditions
Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
Interventions
OnabotulinumtoxinA 100 UNT
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Not applicable Interventional Results available

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

NCT03556891
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
15
States / cities
Downey, California • Redwood City, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 30, 2026, 4:06 PM EDT
Terminated Phase 1 Interventional

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

NCT04311710
View directory record Official record
Conditions
Tumor
Interventions
ipilimumab, nivolumab, ENHANZE (rHuPH20)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Hartford, Connecticut • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Learning to THRIVE (L2T) Program Pilot

NCT07797010
View directory record Official record
Conditions
Interstitial Cystitis and Bladder Pain Syndrome
Interventions
Learning to THRIVE (L2T) Program
Behavioral
Lead sponsor
University of Indianapolis
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome

NCT00919113
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
2% sodium chondroitin sulfate, Placebo
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Boulder, Colorado • Denver, Colorado • Farmington, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Results available

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial

NCT00863551
View directory record Official record
Conditions
Elderly, Pharmacokinetics, Overactive Bladder
Interventions
Trospium Chloride
Drug
Lead sponsor
Allergan
Industry
Eligibility
65 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 30, 2026, 4:06 PM EDT
Not yet recruiting Not applicable Interventional

A Pilot Study Comparison of Programmed Intermittent Bolus Versus Continuous Infusion

NCT07839039
View directory record Official record
Conditions
Bladder Extrophy, Surgery in Children
Interventions
Ropivacaine (Epidural analgesia) intermittent bolus, Ropivacaine (Epidural analgesia) continuous infusion, Chloroprocaine intermittent bolus, Chloroprocaine continuous infusion
Drug
Lead sponsor
Giorgio Veneziano
Other
Eligibility
Up to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Active, not recruiting Not applicable Interventional

SPARC Bladder Mapping and Training Study

NCT03452007
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Epidural Stimulation
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Not applicable Interventional Results available

BULLET: Bladder Ultrasound Limits Length (of Time), Expedites Treatment

NCT03860311
View directory record Official record
Conditions
Point-of-Care Bladder Ultrasound, Urethral Catheter
Interventions
Bladder Ultrasound, Standard of Care
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 18 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 30, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Observational Study of Control Participants for the MAPP Research Network

NCT01098292
View directory record Official record
Conditions
Fibromyalgia, Irritable Bowel Syndrome, Fatigue Syndrome, Chronic
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 30, 2026, 4:06 PM EDT